-
1
-
-
0032946317
-
The Texas Medication Algorithm Project: Development and implementation of the schizophrenia algorithm
-
Chiles JA, Miller AL, Crismon ML, et al. The Texas Medication Algorithm Project: development and implementation of the schizophrenia algorithm. Psychiatr Serv 1999;50:69-74 (Pubitemid 29035359)
-
(1999)
Psychiatric Services
, vol.50
, Issue.1
, pp. 69-74
-
-
Chiles, J.A.1
Miller, A.L.2
Crismon, M.L.3
Rush, A.J.4
Krasnoff, A.S.5
Shon, S.S.6
-
2
-
-
0035029416
-
Short-term inpatient pharmacotherapy of schizophrenia
-
Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry 2001;9:89-104 (Pubitemid 32372934)
-
(2001)
Harvard Review of Psychiatry
, vol.9
, Issue.3
, pp. 89-104
-
-
Osser, D.N.1
Sigadel, R.2
-
3
-
-
33746855617
-
The Expert Consensus Guidelines: Treatment of Behavioral Emergencies 2005
-
Allen MA, Currier GW, Carpenter D, et al. The Expert Consensus Guidelines: Treatment of Behavioral Emergencies 2005. J Psychiatr Pract 2005;11(suppl 1):1-108
-
(2005)
J Psychiatr Pract
, Issue.11 SUPPL. 1
, pp. 1-108
-
-
Allen, M.A.1
Currier, G.W.2
Carpenter, D.3
-
4
-
-
34447321275
-
Ziprasidone for schizophrenia and bipolar disorder: A review of the clinical trials
-
DOI 10.1111/j.1527-3458.2007.00008.x
-
Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev 2007;13:137-177 (Pubitemid 47052346)
-
(2007)
CNS Drug Reviews
, vol.13
, Issue.2
, pp. 137-177
-
-
Greenberg, W.M.1
Citrome, L.2
-
5
-
-
0035012418
-
Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial
-
DOI 10.1007/s002130000658
-
Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001;155:128-134 (Pubitemid 32417820)
-
(2001)
Psychopharmacology
, vol.155
, Issue.2
, pp. 128-134
-
-
Daniel, D.G.1
Potkin, S.G.2
Reeves, K.R.3
Swift, R.H.4
Harrigan, E.P.5
-
6
-
-
7844224760
-
Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
-
DOI 10.1007/s002130050755
-
Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998;140:173-184 (Pubitemid 28538477)
-
(1998)
Psychopharmacology
, vol.140
, Issue.2
, pp. 173-184
-
-
Keck Jr., P.1
Buffenstein, A.2
Ferguson, J.3
Feighner, J.4
Jaffe, W.5
Harrigan, E.P.6
Morrissey, M.R.7
-
7
-
-
0033136622
-
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
-
and the Ziprasidone Study Group
-
Daniel DG, Zimbroff DL, Potkin SG, et al., and the Ziprasidone Study Group. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491-505
-
(1999)
Neuropsychopharmacology
, vol.20
, pp. 491-505
-
-
Daniel, D.G.1
Zimbroff, D.L.2
Potkin, S.G.3
-
8
-
-
0031927910
-
An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder
-
DOI 10.1097/00004714-199808000-00009
-
Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18;296-304 (Pubitemid 28353872)
-
(1998)
Journal of Clinical Psychopharmacology
, vol.18
, Issue.4
, pp. 296-304
-
-
Goff, D.C.1
Posever, T.2
Herz, L.3
Simmons, J.4
Kletti, N.5
Lapierre, K.6
Wilner, K.D.7
Law, C.G.8
Ko, G.N.9
-
9
-
-
0038653525
-
A meta-analysis of the efficacy of second-generation antipsychotics
-
DOI 10.1001/archpsyc.60.6.553
-
Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564 (Pubitemid 36682312)
-
(2003)
Archives of General Psychiatry
, vol.60
, Issue.6
, pp. 553-564
-
-
Davis, J.M.1
Chen, N.2
Glick, I.D.3
-
10
-
-
13744256171
-
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: An 8-week, double-blind, multicenter trial
-
Addington DEN, Pantelis C, Dineen M, et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004;65:1624-1633
-
(2004)
J Clin Psychiatry
, vol.65
, pp. 1624-1633
-
-
Addington, D.E.N.1
Pantelis, C.2
Dineen, M.3
-
11
-
-
4744338410
-
Randomized, controlled, double-blind multicenter comparison, of the efficacy and tolerability of ziprasidone and olanzapine in acutely III inpatients with schizophrenia or schizoaffective disorder
-
DOI 10.1176/appi.ajp.161.10.1837
-
Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:1837-1847 (Pubitemid 39314678)
-
(2004)
American Journal of Psychiatry
, vol.161
, Issue.10
, pp. 1837-1847
-
-
Simpson, G.M.1
Glick, I.D.2
Weiden, P.J.3
Romano, S.J.4
Siu, C.O.5
-
12
-
-
34948813543
-
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, 4-week study
-
DOI 10.1097/YIC.0b013e32816f7779, PII 0000485020071100000007
-
Zimbroff D, Warrington L, Loebel A, et al. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol 2007;22:363-370 (Pubitemid 47530841)
-
(2007)
International Clinical Psychopharmacology
, vol.22
, Issue.6
, pp. 363-370
-
-
Zimbroff, D.1
Warrington, L.2
Loebel, A.3
Yang, R.4
Siu, C.5
-
13
-
-
26444456116
-
Olanzapine versus ziprasidone: Results of a 23-week double-blind study in patients with schizophrenia
-
DOI 10.1176/appi.ajp.162.10.1879
-
Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162:1879-1887 (Pubitemid 41428617)
-
(2005)
American Journal of Psychiatry
, vol.162
, Issue.10
, pp. 1879-1887
-
-
Breier, A.1
Berg, P.H.2
Thakore, J.H.3
Naber, D.4
Gattaz, W.F.5
Cavazzoni, P.6
Walker, D.J.7
Roychowdhury, S.M.8
Kane, J.M.9
-
14
-
-
33646681652
-
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms
-
DOI 10.1097/01.jcp.0000204137.82298.06, PII 0000471420060400000008
-
Kinon BJ, Lipkovich I, Edwards SB, et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006;26:157-162 (Pubitemid 43740339)
-
(2006)
Journal of Clinical Psychopharmacology
, vol.26
, Issue.2
, pp. 157-162
-
-
Kinon, B.J.1
Lipkovich, I.2
Edwards, S.B.3
Adams, D.H.4
Ascher-Svanum, H.5
Siris, S.G.6
-
15
-
-
25144456112
-
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
-
for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
-
Lieberman JA, Stroup TS, McEvoy JP, et al., for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
-
(2005)
N Engl J Med
, vol.353
, pp. 1209-1223
-
-
Lieberman, J.A.1
Stroup, T.S.2
McEvoy, J.P.3
-
16
-
-
85047695988
-
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic
-
DOI 10.1176/appi.ajp.163.4.611
-
Stroup TS, Lieberman JA, McEvoy JP, et al, for the CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-622 (Pubitemid 44464570)
-
(2006)
American Journal of Psychiatry
, vol.163
, Issue.4
, pp. 611-622
-
-
Stroup, T.S.1
Lieberman, J.A.2
McEvoy, J.P.3
Swartz, M.S.4
Davis, S.M.5
Rosenheck, R.A.6
Perkins, D.O.7
Keefe, R.S.E.8
Davis, C.E.9
Severe, J.10
Hsiao, J.K.11
-
17
-
-
1342328623
-
Tolerability of ziprasidone: An expanding perspective
-
Daniel DG. Tolerability of ziprasidone: an expanding perspective. J Clin Psychiatry 2003;64(suppl 19):40-49
-
(2003)
J Clin Psychiatry
, vol.64
, Issue.SUPPL. 19
, pp. 40-49
-
-
Daniel, D.G.1
-
18
-
-
84921432808
-
Ziprasidone for schizophrenia and severe mental illness
-
Cochrane Review. CD001945
-
Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness (Cochrane Review). Cochrane Database Syst Rev 2000;(4):CD001945
-
(2000)
Cochrane Database Syst Rev
, Issue.4
-
-
Bagnall, A.1
Lewis, R.A.2
Leitner, M.L.3
-
19
-
-
0032751075
-
Antipsychotic-induced weight gain: A comprehensive research synthesis
-
Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696 (Pubitemid 29517559)
-
(1999)
American Journal of Psychiatry
, vol.156
, Issue.11
, pp. 1686-1696
-
-
Allison, D.B.1
Mentore, J.L.2
Heo, M.3
Chandler, L.P.4
Cappelleri, J.C.5
Infante, M.C.6
Weiden, P.J.7
-
20
-
-
40549118840
-
Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone
-
Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008;33:985-994
-
(2008)
Neuropsychopharmacology
, vol.33
, pp. 985-994
-
-
Weiden, P.J.1
Newcomer, J.W.2
Loebel, A.D.3
-
21
-
-
34047173462
-
A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia
-
on behalf of the ZIS Study Group
-
Arango C, Gomez-Beneyto M, Brenlla J, et al, on behalf of the ZIS Study Group. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. Eur Neuropsychopharmacol 2007;17:456-463
-
(2007)
Eur Neuropsychopharmacol
, vol.17
, pp. 456-463
-
-
Arango, C.1
Gomez-Beneyto, M.2
Brenlla, J.3
-
22
-
-
34548137741
-
Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: A 12-month, open-label, flexible-dose, naturalistic observational trial
-
DOI 10.1016/j.pnpbp.2007.06.008, PII S0278584607001996
-
Ratner Y, Gibel A, Yorkov V, et al. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1401-1409 (Pubitemid 47302551)
-
(2007)
Progress in Neuro-Psychopharmacology and Biological Psychiatry
, vol.31
, Issue.7
, pp. 1401-1409
-
-
Ratner, Y.1
Gibel, A.2
Yorkov, V.3
Ritsner, M.S.4
-
23
-
-
0003248994
-
Expanding the frontier of treatment research
-
published online Mar 21, 1999. ArtID1a. doi: 10.1037/1522-3736.2.1.21a
-
Norquist G, Lebowitz B, Hyman S. Expanding the frontier of treatment research [published online Mar 21, 1999]. Prev Treatment 1999;2(1):ArtID1a. doi: 10.1037/1522-3736.2.1.21a
-
(1999)
Prev Treatment
, vol.2
, Issue.1
-
-
Norquist, G.1
Lebowitz, B.2
Hyman, S.3
-
24
-
-
0002278232
-
Expert Consensus Guideline Series: Treatment of Schizophrenia 1999
-
Expert Consensus Guideline Series: Treatment of Schizophrenia 1999. J Clin Psychiatry 1999;60(suppl 11):1-80
-
(1999)
J Clin Psychiatry
, vol.60
, Issue.SUPPL. 11
, pp. 1-80
-
-
-
25
-
-
0032923291
-
Treatment research at the crossroads: The scientific interface of clinical trials and effectiveness research
-
Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry 1999;156:5-10 (Pubitemid 29034873)
-
(1999)
American Journal of Psychiatry
, vol.156
, Issue.1
, pp. 5-10
-
-
Wells, K.B.1
-
26
-
-
0033987870
-
Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia
-
Woods SW, Ziedonis DM, Sernyak MJ, et al. Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia. Psychiatr Serv 2000;51:79-84 (Pubitemid 30036753)
-
(2000)
Psychiatric Services
, vol.51
, Issue.1
, pp. 79-84
-
-
Woods, S.W.1
Ziedonis, D.M.2
Sernyak, M.J.3
Diaz, E.4
Rosenheck, R.A.5
-
27
-
-
0028003837
-
Neuroleptic dose and schizophrenic symptoms. a survey of prescribing practices
-
Peralta V, Cuesta MJ, Caro F, et al. Neuroleptic dose and schizophrenic symptoms: a survey of prescribing practices. Acta Psychiatr Scand 1994;90:354-357 (Pubitemid 24331608)
-
(1994)
Acta Psychiatrica Scandinavica
, vol.90
, Issue.5
, pp. 354-357
-
-
Peralta, V.1
Cuesta, M.J.2
Caro, F.3
Martinez-Larrea, A.4
-
29
-
-
33749326014
-
Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries
-
DOI 10.1097/01.yic.0000224785.68040.43, PII 0000485020061100000005
-
Barbui C, Nose M, Mazzi MA, et al. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 2006;21:355-362 (Pubitemid 44498277)
-
(2006)
International Clinical Psychopharmacology
, vol.21
, Issue.6
, pp. 355-362
-
-
Barbui, C.1
Nose, M.2
Mazzi, M.A.3
Thornicroft, G.4
Schene, A.5
Becker, T.6
Bindman, J.7
Leese, M.8
Helm, H.9
Koeter, M.10
Weinmann, S.11
Tansella, M.12
-
30
-
-
34248993215
-
Factors associated with antipsychotic dosing in psychiatric inpatients: A prospective study
-
DOI 10.1097/YIC.0b013e3281084ea8, PII 0000485020070700000006
-
Barbui C, Biancosino B, Esposito E, et al. Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 2007;22:221-225 (Pubitemid 46801945)
-
(2007)
International Clinical Psychopharmacology
, vol.22
, Issue.4
, pp. 221-225
-
-
Barbui, C.1
Biancosino, B.2
Esposito, E.3
Marmai, L.4
Dona, S.5
Grassi, L.6
-
31
-
-
66349107022
-
Outcome measurement from research to clinical practice
-
IsHak WW, Burt T, Sederer LI, eds. Washington, DC: American Psychiatric Publishing Inc
-
Dickey B. Outcome measurement from research to clinical practice. In: IsHak WW, Burt T, Sederer LI, eds. Outcome Measurement in Psychiatry: A Critical Review. Washington, DC: American Psychiatric Publishing Inc; 2002:15-22
-
(2002)
Outcome Measurement in Psychiatry: A Critical Review
, pp. 15-22
-
-
Dickey, B.1
-
32
-
-
0036695527
-
The 2 "Es" of research: Efficacy and effectiveness trials
-
Streiner DL. The 2 "Es" of research: efficacy and effectiveness trials. Can J Psychiatry 2002;47:552-556
-
(2002)
Can J Psychiatry
, vol.47
, pp. 552-556
-
-
Streiner, D.L.1
-
33
-
-
0000503515
-
The Brief Psychiatric Rating Scale
-
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
-
(1962)
Psychol Rep
, vol.10
, pp. 799-812
-
-
Overall, J.E.1
Gorham, D.R.2
-
34
-
-
0003412410
-
-
US Dept Health, Education, and Welfare publication (ADM) No 76-338. Rockville, Md: National Institute of Mental Health
-
Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. US Dept Health, Education, and Welfare publication (ADM) No 76-338. Rockville, Md: National Institute of Mental Health; 1976:157-165
-
(1976)
ECDEU Assessment Manual for Psychopharmacology-Revised
, pp. 157-165
-
-
Guy, W.1
-
35
-
-
0003412410
-
-
US Dept Health, Education, and Welfare publication (ADM) No 76-338. Rockville, Md: National Institute of Mental Health
-
Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. US Dept Health, Education, and Welfare publication (ADM) No 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
-
(1976)
ECDEU Assessment Manual for Psychopharmacology-Revised
, pp. 218-222
-
-
Guy, W.1
-
36
-
-
0020535524
-
A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity
-
Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-183 (Pubitemid 13132147)
-
(1983)
Psychological Medicine
, vol.13
, Issue.1
, pp. 177-183
-
-
Hogan, T.P.1
Awad, A.G.2
Eastwood, R.3
-
37
-
-
0034804963
-
El Cuestionario de Actitud hacia la Medicación (Drug Attitude Inventory: DAI-30) en población española
-
Garcia I, Hormaechea JA, Arango C, et al. El Cuestionario de Actitud hacia la Medicación (Drug Attitude Inventory: DAI-30) en población española. Arch Psiquiatr 2001;64;261-272
-
(2001)
Arch Psiquiatr
, vol.64
, pp. 261-272
-
-
Garcia, I.1
Hormaechea, J.A.2
Arango, C.3
-
38
-
-
0028027827
-
Awareness of illness in schizophrenia and schizoaffective and mood disorders
-
Amador XF, Flaum M, Andreason NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry 1994;51:826-836 (Pubitemid 24313308)
-
(1994)
Archives of General Psychiatry
, vol.51
, Issue.10
, pp. 826-836
-
-
Amador, X.F.1
Flaum, M.2
Andreasen, N.C.3
Strauss, D.H.4
Yale, S.A.5
Clark, S.C.6
Gorman, J.M.7
-
39
-
-
33645051491
-
Clinical trials for antipsychotic drugs: Design conventions, dilemmas, and innovations
-
Stroup TS, Alves WM, Hamer RM, et al. Clinical trials for antipsychotic drugs: design conventions, dilemmas, and innovations. Nat Rev Drug Discov 2006;5:133-146
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 133-146
-
-
Stroup, T.S.1
Alves, W.M.2
Hamer, R.M.3
-
40
-
-
0024638447
-
Effect sizes for interpreting changes in health status
-
Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27:S178-S189
-
(1989)
Med Care
, vol.27
-
-
Kazis, L.E.1
Anderson, J.J.2
Meenan, R.F.3
-
41
-
-
0036788207
-
Insight into illness and attitudes toward medications among inpatients with schizophrenia
-
Sajatovic M, Rosch DS, Sivec HJ, et al. Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv 2002;53:1319-1321
-
(2002)
Psychiatr Serv
, vol.53
, pp. 1319-1321
-
-
Sajatovic, M.1
Rosch, D.S.2
Sivec, H.J.3
-
42
-
-
0037212062
-
Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia: A naturalistic study
-
for the EUROPA Study Group
-
Alvarez E, Bobes J, Gomez JC, et al, for the EUROPA Study Group. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia: a naturalistic study. Eur Neuropsychopharmacol 2003;13:39-48
-
(2003)
Eur Neuropsychopharmacol
, vol.13
, pp. 39-48
-
-
Alvarez, E.1
Bobes, J.2
Gomez, J.C.3
-
43
-
-
33847768125
-
Tolerability and effectiveness of quetiapine in inpatients with schizophrenia: Results from the acute phase of the TESIS study
-
Abstract
-
Perez V, Cañas F, Tafalla M, et al. Tolerability and effectiveness of quetiapine in inpatients with schizophrenia: results from the acute phase of the TESIS study [Abstract]. Eur Neuropsychopharmacol 2005;15(suppl 3):S493
-
(2005)
Eur Neuropsychopharmacol
, vol.15
, Issue.SUPPL. 3
-
-
Perez, V.1
Cañas, F.2
Tafalla, M.3
-
44
-
-
33645846052
-
Effect of initial ziprasidone dose on treatment persistence in schizophrenia
-
Mullins CD, Shaya FT, Zito JM, et al. Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophr Res 2006;83:277-284
-
(2006)
Schizophr Res
, vol.83
, pp. 277-284
-
-
Mullins, C.D.1
Shaya, F.T.2
Zito, J.M.3
-
45
-
-
33947729686
-
Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial
-
DOI 10.1016/j.eurpsy.2006.06.004, PII S0924933806001325
-
Kudla D, Lambert M, Domin S, et al. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial. Eur Psychiatry 2007;22:195-202 (Pubitemid 46507733)
-
(2007)
European Psychiatry
, vol.22
, Issue.3
, pp. 195-202
-
-
Kudla, D.1
Lambert, M.2
Domin, S.3
Kasper, S.4
Naber, D.5
-
46
-
-
66349136964
-
Impact of real-world ziprasidone dosing on treatment discontinuation rates in subjects with schizophrenia or bipolar disorder
-
Abstract NR6-105:323
-
Citrome L, Reist C, Palmer L, et al. Impact of real-world ziprasidone dosing on treatment discontinuation rates in subjects with schizophrenia or bipolar disorder. In: New Research Program and Abstracts of the 161st annual meeting of the American Psychiatric Association; May 3-8, 2008; Washington, DC. Abstract NR6-105:323
-
New Research Program and Abstracts of the 161st Annual Meeting of the American Psychiatric Association; May 3-8, 2008; Washington, DC
-
-
Citrome, L.1
Reist, C.2
Palmer, L.3
-
47
-
-
34548847495
-
The "Seroquel" Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia
-
for the SOS GROUP
-
Gibert J, Giner J, Bobes J, et al, for the SOS GROUP. The "Seroquel" Outcomes Study (SOS): efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia. Int J Psychiatry Clin Pract 2007;11:222-232
-
(2007)
Int J Psychiatry Clin Pract
, vol.11
, pp. 222-232
-
-
Gibert, J.1
Giner, J.2
Bobes, J.3
-
48
-
-
0036735166
-
Optimal dosing of atypical antipsychotics in adults: A review of the current evidence
-
Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry 2002;10:280-291
-
(2002)
Harv Rev Psychiatry
, vol.10
, pp. 280-291
-
-
Citrome, L.1
Volavka, J.2
-
49
-
-
0035015262
-
Dose selection and comparator drugs in schizophrenia research
-
Kane JM. Dose selection and comparator drugs in schizophrenia research. J Clin Psychiatry 2001;62(suppl 9):29-32 (Pubitemid 32452718)
-
(2001)
Journal of Clinical Psychiatry
, vol.62
, Issue.SUPPL. 9
, pp. 29-34
-
-
Kane, J.M.1
-
50
-
-
1542776092
-
The Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders: Introduction: methods, commentary, and summary
-
Kane JM, Leucht S, Carpenter D, et al. The Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders: Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(suppl 12):5-19
-
(2003)
J Clin Psychiatry
, vol.64
, Issue.SUPPL. 12
, pp. 5-19
-
-
Kane, J.M.1
Leucht, S.2
Carpenter, D.3
-
52
-
-
66349116120
-
The relationship between clinical efficacy and quality of life: A randomized, 40-week, double-blind study of ziprasidone versus haloperidol followed by a 3-year, double-blind extension phase
-
Abstract NR 515:221
-
Stahl SM, Malla AK, Newcomer JW, et al. The relationship between clinical efficacy and quality of life: a randomized, 40-week, double-blind study of ziprasidone versus haloperidol followed by a 3-year, double-blind extension phase. In: New Research Program and Abstracts of the 160th annual meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, Calif. Abstract NR 515:221
-
New Research Program and Abstracts of the 160th Annual Meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, Calif.
-
-
Stahl, S.M.1
Malla, A.K.2
Newcomer, J.W.3
-
53
-
-
38549180032
-
Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia
-
Rocca P, Crivelli B, Marino F, et al. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. Compr Psychiatry 2008;49:170-176
-
(2008)
Compr Psychiatry
, vol.49
, pp. 170-176
-
-
Rocca, P.1
Crivelli, B.2
Marino, F.3
-
54
-
-
35649028046
-
Correlates and long-term consequences of poor insight in patients with schizophrenia. a systematic review
-
DOI 10.1093/schbul/sbm002
-
Lincoln TM, Lullmann E, Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia: a systematic review. Schizophr Bull 2007;33:1324-1342 (Pubitemid 350022767)
-
(2007)
Schizophrenia Bulletin
, vol.33
, Issue.6
, pp. 1324-1342
-
-
Lincoln, T.M.1
Lullmann, E.2
Rief, W.3
-
55
-
-
10144255847
-
Ziprasidone: First year experience in a hospital setting
-
DOI 10.1097/00131746-200411000-00004
-
Centorrino F, MacLean E, Salvatore P, et al. Ziprasidone: first year experience in a hospital setting. J Psychiatr Pract 2004;10:361-367 (Pubitemid 39614269)
-
(2004)
Journal of Psychiatric Practice
, vol.10
, Issue.6
, pp. 361-367
-
-
Centorrino, F.1
Maclean, E.2
Salvatore, P.3
Kidwell, J.E.4
Fogarty, K.V.5
Berry, J.M.6
Baldessarini, R.J.7
-
56
-
-
44849131431
-
The effect of food on the absorption of oral ziprasidone
-
Miceli JJ, Glue P, Alderman J, et al. The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull 2007;40:58-68
-
(2007)
Psychopharmacol Bull
, vol.40
, pp. 58-68
-
-
Miceli, J.J.1
Glue, P.2
Alderman, J.3
|